Form 4: RA Capital Management Reports Director Stock Option Grant in Climb Bio, Inc.

RA Capital Management, a significant shareholder and director of Climb Bio, Inc., has reported the acquisition of 40,000 stock options for Climb Bio common stock at an exercise price of $1.29, granted to Dr. Andrew Levin, a Partner and Managing Director of RA Capital who serves on the Issuer's board.

Summary

• RA Capital Management, L.P., along with its associated funds (RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund II, RA Capital Nexus Fund III) and managing members (Peter Kolchinsky and Rajeev Shah), filed a Form 4 reporting an insider transaction.
• The transaction involves the acquisition of 40,000 stock options for Climb Bio, Inc. (CLYM) common stock.
• The options were granted on June 4, 2025, with an exercise price of $1.29 per share and an expiration date of June 3, 2035.
• These options were granted to Dr. Andrew Levin, a Partner and Managing Director of RA Capital Management, L.P., who also serves on Climb Bio's board of directors.
• The shares subject to the option will vest on the earlier of June 4, 2026, or the day immediately prior to the next annual meeting of stockholders, contingent on Dr. Levin's continuous service.
• Dr. Levin holds these options for the benefit of the RA Capital funds and a separately managed account, and is obligated to turn over any net cash or stock received upon exercise to RA Capital Management, which will offset advisory fees owed by the funds.
• The reporting persons (RA Capital entities and individuals) disclaim beneficial ownership of the options and underlying common stock, except to the extent of their respective pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing reporting an insider transaction (stock option grant). It contains factual information about the grant and its terms, with no overtly positive or negative language regarding company performance or outlook. The transaction itself is a routine compensation event for a director.

Positives

• The grant of stock options to a director associated with a major investor (RA Capital) helps align the interests of a key stakeholder with the long-term performance of Climb Bio, Inc.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, as 40,000 new shares of common stock would be issued.

Risks

• The value of the stock options is dependent on Climb Bio's stock price exceeding the exercise price of $1.29; if the stock price remains below this level, the options may not be exercised.
• The vesting of the options is subject to Dr. Andrew Levin's continuous service, posing a risk if his service is terminated before the vesting conditions are met.

Future Outlook

The stock options granted are set to vest on the earlier of June 4, 2026, or the day prior to the next annual meeting of stockholders, subject to continuous service. This indicates a future potential increase in outstanding shares if the options are exercised, aligning a key director's incentives with long-term company performance.

Management Comments

• "The shares subject to the option will vest on the earlier of June 4, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's continuous service through such date."
• "RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account."
• "Dr. Andrew Levin is a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors. Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account."
• "Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser."
• "The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock, except to the extent of its or his respective pecuniary interest therein."

Industry Context

The granting of stock options to directors, particularly those representing significant institutional investors, is a common practice in the biotechnology and broader corporate sectors. It serves to align the interests of board members with shareholder value creation and is a standard component of director compensation packages.

Corporate Governance

Related Party Transactions

• The grant of 40,000 stock options to Dr. Andrew Levin, a director of Climb Bio, Inc., who is also a Partner and Managing Director of RA Capital Management, L.P., a 10% owner of Climb Bio, Inc. This constitutes a related party transaction, structured to benefit the RA Capital funds.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon future exercise of the options, but also improved alignment of interests with a director representing a significant institutional investor.
• RA Capital Management and its Funds: Direct beneficiaries of the option grant, as proceeds from exercise will offset advisory fees, enhancing their pecuniary interest in Climb Bio's performance.

Next Steps

• Monitoring the vesting of the 40,000 stock options granted to Dr. Andrew Levin, which will occur on the earlier of June 4, 2026, or the day prior to the next annual meeting of stockholders.
• Observing any future exercise of these options, which would result in the issuance of common stock.

Key Dates

Keywords

SEC Form 4, Climb Bio Inc., CLYM, RA Capital Management, Stock Option, Insider Transaction, Beneficial Ownership, Director Compensation, Equity Grant, Biotechnology